Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duratil
- Development stage
- Unknown
- Lead developer
- GP Pharm
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Duratil is a teriparatide formulation developed by GP Pharma for the treatment of osteoporosis in patients at high risk of fracture. As a recombinant human parathyroid hormone (PTH 1-34) analog, it acts as a PTH receptor agonist. When administered intermittently via subcutaneous injection, it stimulates osteoblastic activity, promoting new bone formation and increasing bone mineral density. It is marketed as a cost-effective generic or biosimilar alternative to the reference teriparatide products, particularly in the Spanish market where it is classified as an Equivalente Farmacéutico Genérico (EFG).
- Brand names
- Duratil
- Other names
- teriparatideteriparatida
Beyond the preview
Go deeper on Duratil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duratil.